Many Required Postmarketing Studies for New Drugs Never Completed

The FDA often approves new drugs with the caveat that the manufacturer complete postmarketing studies to confirm the safety and efficacy of these medicines. However, a new analysis indicates that barely half of these required studies are completed years later.

Steve Woloshin, MD, and Lisa Schwartz, MD, both of the Dartmouth Institute for Health Policy & Clinical Practice, and their colleagues looked at records and found 614 postapproval studies for new drugs that were required by the FDA in 2009 and 2010. Between 5 and 6 years later, only 54% of those studies had been completed, they reported in the New England Journal of Medicine.

But even more shocking, about 20% of those studies hadn’t even been started, and 25% were either ongoing or delayed — despite a 2007 law granting the FDA additional powers to mandate such studies. The law came in response to criticism that too many drugmakers weren’t completing the studies. The legislation also gave the FDA the authority to set timelines for when study designs and the studies themselves should be completed, as well as to levy fines on manufacturers and even rescind approval if those deadlines are not met.

The findings are a concern, given that many new drugs are approved based on trials with a relatively short duration. In addition, the Trump administration has been pushing for more rapid approval of drugs by relaxing approval standards. However, side effects may not become evident until a person is on a medication for some time, and that can only happen with longer duration post-marketing trials.

One example cited in the analysis is for the medication Suboxone (buprenorphine and naloxone), which is used to treat opioid dependence. In the clinical trials that supported approval, there were questions that the drug might lead to a heart issue. The authors say Suboxone’s manufacturer was given a year to submit a trial design and 5 years to complete the trial. As of July of this year, they say, the design – known as a study protocol –- had yet to be submitted.

The authors recommend that the FDA set shorter deadlines for completion of post-approval studies as one way of dealing with the problem. They also say the agency should use its power to impose penalties on drugmakers that fail to meet deadlines since to their knowledge, the FDA has never done so.

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.

Did you find this article helpful?

Notify of
Inline Feedbacks
View all comments

Latest News

Covid-19: Side Effects of Trump’s Treatments

Covid-19: Side Effects of Trump’s Treatments

President Donald Trump announced (via Twitter, of course) what some considered unthinkable, and others considered inevitable — that he had tested positive for Covid-19. Over the weekend, he received various treatments  — supplements like vitamin D, zinc and melatonin, an experimental antibody combination, an antiviral drug and a powerful anti-inflammatory…

Un-Sheltering Tips for Your Health and Immune System

Un-Sheltering Tips for Your Health and Immune System

As we all emerge from our bubbles of limited contact with others, we are walking straight into the double whammy of flu season and COVID-19 germs. Can your body fight off exposure to the flu and COVID? Your immune system feeds off the basics of life — sleep, movement, food…

  • [class^="wpforms-"]